Type 1 Diabetes Clinical Trial
Official title:
The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes
In this protocol, 60 subjects with DM1 will be studied at baseline, after 12 weeks of MCR
blockade or 12 weeks of exercise, and again after an additional 12 weeks of MCR blockade,
exercise or the combination of both interventions. The investigators will assess function in
conduit (pulse wave velocity-PWV, flow-mediated dilation-FMD and augmentation index-AI),
resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular
(contrast enhanced ultrasound-CEU) vessels before and after 2 hrs of a euglycemic insulin
clamp.
We hypothesize that compared to healthy controls, both baseline and insulin-responsive
vascular function are impaired throughout the arterial vasculature by DM1 and that exercise
training and/or mineralocorticoid receptor (MCR) blockade will improve both baseline and
insulin-responsive pan-arterial function.
Using non-invasive methods, several small studies have demonstrated conduit artery stiffness
and other small studies report impaired brachial artery nitric oxide (NO) release in subjects
with type diabetes (DM1). Vascular insulin action (characterized by insulin-induced
NO-mediated vasodilation of conduit, resistance or microvascular vessels) has not been
studied systematically in DM1. The investigators hypothesize that compared to healthy
controls, both baseline and insulin-responsive vascular function are impaired throughout the
arterial vasculature by DM1 and that exercise training and/or mineralocorticoid receptor
(MCR) blockade will improve both baseline and insulin-responsive pan-arterial function.
In this protocol, 60 subjects with DM1 will be studied at baseline, after 12 weeks of MCR
blockade or 12 weeks of exercise, and again after an additional 12 weeks of MCR blockade,
exercise or the combination of both interventions. Investigators will assess function in
conduit (pulse wave velocity-PWV, flow-mediated dilation-FMD and augmentation index-AI),
resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular
(contrast enhanced ultrasound-CEU) vessels before and after 2 hrs of a euglycemic insulin
clamp.
This work will: a) identify whether vascular stiffness and indices of NO action are impaired
throughout the arterial tree in DM1; b) identify the impact of fitness, MCR blockade or the
combination to improve vascular function; and c) introduce a rational paradigm for early,
proof-of-concept testing of interventions that may improve vascular health in DM1. While
multiple endpoints are measured in the proposed studies, the investigators designate one
primary conduit vessel endpoint (augmentation index) and one primary microvascular endpoint
(microvascular blood volume by CEU); the studies are powered on these measures. The
investigators believe that their laboratories are in a unique position with respect to their
demonstrated scientific expertise to deliver this fundamental information.
The study proposed here will be the first to assess whether: 1) basal pan-arterial function
including myocardial microvascular function is adversely affected by DM1 ; 2) vascular
insulin responsiveness in DM1 is impaired as is seen in DM2 3) exercise training or MCR
blockade alone or in combination favorably impacts vascular stiffness or NO-induced
relaxation in DM1 in the basal state or in response to insulin. This non-invasive vascular
profiling provides a functional "biomarker" of pan-arterial health. As such it could be
useful for assessing the impact of specific short-term interventions on critical vascular
functions in small scale studies (e.g. MCR blockade, statins, GLP-1R agonists) and thereby
provide a rationale for selection of candidate therapies for subsequent larger clinical
outcome trials. Additionally, non-invasive assessment of pan-arterial function could provide
a platform to identify patients for early or more intensive treatment interventions as part
of their care plan.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|